This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Harshman LC , Chen YH , Liu G , Carducci MA , Jarrard D , Dreicer R , Hahn N , Garcia JA , Hussain M , Shevrin D , Eisenberger M , Kohli M , Plimack ER , Cooney M , Vogelzang NJ , Picus J , Dipaola R , Sweeney CJ
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
J Clin Oncol. 2018 Feb 1;36(4) :376-382
PMID: 29261442 PMCID: PMC5805480
AbstractPurpose We evaluated the relationship between prostate-specific antigen (PSA) and overall survival in the context of a prospectively randomized clinical trial comparing androgen-deprivation therapy (ADT) plus docetaxel with ADT alone for initial metastatic hormone-sensitive prostate cancer. Methods We performed a landmark survival analysis at 7 months using the E3805 Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) database ( ClinicalTrials.gov identifier: NCT00309985). Inclusion required at least 7 months of follow-up and PSA levels at 7 months from ADT initiation. We used the prognostic classifiers identified in a previously reported trial (Southwest Oncology Group 9346) of PSA </= 0.2, > 0.2 to 4, and > 4 ng/mL. Results Seven hundred nineteen of 790 patients were eligible for this subanalysis; 358 were treated with ADT plus docetaxel, and 361 were treated with ADT alone. Median follow-up time was 23.1 months. On multivariable analysis, achieving a 7-month PSA </= 0.2 ng/mL was more likely with docetaxel, low-volume disease, prior local therapy, and lower baseline PSAs (all P </= .01). Across all patients, median overall survival was significantly longer if 7-month PSA reached </= 0.2 ng/mL compared with > 4 ng/mL (median survival, 60.4 v 22.2 months, respectively; P < .001). On multivariable analysis, 7-month PSA </= 0.2 and low volume disease were prognostic of longer overall survival (all P < 0.01). The addition of docetaxel increased the likelihood of achieving a PSA </= 0.2 ng/mL at 7 months (45.3% v 28.8% of patients on ADT alone). Patients on ADT alone who achieved a 7-month PSA </= 0.2 ng/mL had the best survival and were more likely to have low-volume disease (56.7%). Conclusion PSA </= 0.2 ng/mL at 7 months is prognostic for longer overall survival with ADT for metastatic hormone-sensitive prostate cancer irrespective of docetaxel administration. Adding docetaxel increased the likelihood of a lower PSA and improved survival.
Notes1527-7755 Harshman, Lauren C Chen, Yu-Hui Liu, Glenn Carducci, Michael A Jarrard, David Dreicer, Robert Hahn, Noah Garcia, Jorge A Hussain, Maha Shevrin, Daniel Eisenberger, Mario Kohli, Manish Plimack, Elizabeth R Cooney, Matthew Vogelzang, Nicholas J Picus, Joel Dipaola, Robert Sweeney, Christopher J ECOG-ACRIN 3805 Investigators UG1 CA189829/CA/NCI NIH HHS/United States P50 CA180995/CA/NCI NIH HHS/United States U10 CA180802/CA/NCI NIH HHS/United States U10 CA180821/CA/NCI NIH HHS/United States U10 CA180801/CA/NCI NIH HHS/United States U10 CA180795/CA/NCI NIH HHS/United States U10 CA180847/CA/NCI NIH HHS/United States U10 CA180790/CA/NCI NIH HHS/United States U10 CA180820/CA/NCI NIH HHS/United States U10 CA180833/CA/NCI NIH HHS/United States U10 CA180794/CA/NCI NIH HHS/United States U10 CA180867/CA/NCI NIH HHS/United States U10 CA180888/CA/NCI NIH HHS/United States U10 CA180853/CA/NCI NIH HHS/United States Comparative Study Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States J Clin Oncol. 2018 Feb 1;36(4):376-382. doi: 10.1200/JCO.2017.75.3921. Epub 2017 Dec 20.